ENGINEERED PROTEINS TO REPAIR OR REGROW DAMAGED HEART MUSCLE CELLS AND TISSUE
Associate Professor Dan Hesselson,
Head of the Centre for Biomedical AI,
Centenary Institute
Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | July 2026
Associate Professor Dan Hesselson leads the Centre for Biomedical AI at the Centenary Institute.
He is an internationally trained research leader in regenerative medicine, focusing on cells and organs affected by heart disease, diabetes and cancer. His work uses insights from the study of basic regenerative processes to identify novel therapeutic targets for these devastating diseases.
His work with zebrafish, which started at University of California San Francisco (UCSF) and was expanded at the Garvan Institute, made significant contributions to our understanding of the molecular mechanisms of regeneration in this highly regenerative model system.
At the Centenary Institute, he is focused on exploiting these breakthroughs in basic science to develop new therapeutic strategies using the power of Directed Evolution to generate potent and highly specific biologic drugs.
His research is investigating new ways to repair the heart and improve outcomes for individuals recovering from heart attacks or living with heart disease, aiming to address a critical gap in cardiac care.
While current treatments can manage symptoms, they cannot restore heart function once muscle cells are lost. This irreversible damage is why heart failure remains a leading cause of death worldwide.
Associate Professor Hesselson’s research aims to address this challenge by developing therapies based on engineered proteins capable of repairing or regrowing damaged heart muscle cells and tissue.
Source: Supplied and adapted from Centenary Institute media release (June 2026)
-
Supportive care for people living with or beyond cancer treatment
Dr Hannah Wardill is a Hospital Research Foundation Fellow and lead of the Supportive Oncology Research Group (SORG), in the School of Biomedicine, University of Adelaide and Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI). She is an Executive Board Member of the Multinational Association for Supportive Care in Cancer / International Society for Oral Oncology (MASCC/ISOO) and Chair of both MASCC/ISOO Patient Partnership Committee & the Palliative Care Clinical Studies Collaborative (PaCCSC) Cancer Symptom Trials (Gut Dysfunction Node; supported by Cancer Australia).
-
Lymphoma, Myeloma and Genomics
Professor Dipti Talaulikar is a clinical and laboratory haematologist with expertise in genomics, working at Canberra Health Services, and Professor at ANU. She has a clinical and research interest in lymphoma, myeloma and genomics, and has authored close to 100 peer reviewed papers, including several clinical guidelines that have had a significant impact on clinical practice.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
